Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
80.93
+2.70 (3.45%)
Jun 11, 2026, 10:58 AM EDT - Market open

Kymera Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
6,6576,3282,6111,4151,3743,272
Market Cap Growth
263.29%142.39%84.46%3.02%-58.01%18.64%
Enterprise Value
4,9705,5622,2101,125983.952,848
Last Close Price
80.9377.8140.2325.4624.9663.49
PS Ratio
125.01161.3855.4618.0129.3444.93
PB Ratio
4.184.013.123.582.807.12
P/TBV Ratio
4.674.163.613.762.756.63
EV/Sales Ratio
96.55141.8446.9414.3121.0139.10
Debt / Equity Ratio
0.040.040.090.200.030.03
Net Debt / Equity Ratio
-0.37-0.48-0.48-0.73-0.79-0.92
Net Debt / EBITDA Ratio
1.632.251.581.792.464.33
Net Debt / FCF Ratio
2.343.271.932.112.503.25
Asset Turnover
0.030.030.060.130.080.13
Quick Ratio
10.3910.197.214.595.744.78
Current Ratio
10.8110.477.534.735.884.88
Return on Equity (ROE)
-20.20%-25.78%-36.38%-33.21%-32.60%-26.96%
Return on Assets (ROA)
-21.05%-25.68%-33.68%-28.08%-26.68%-18.39%
Return on Invested Capital (ROIC)
-37.51%-49.80%-73.71%-75.51%-72.73%-40.14%
Return on Capital Employed (ROCE)
-21.99%-27.19%-37.37%-32.40%-30.86%-22.59%
Buyback Yield / Dilution
-14.79%-12.59%-28.58%-8.22%-12.39%-176.60%
Total Shareholder Return
-14.79%-12.59%-28.58%-8.22%-12.39%-176.60%
SEC Filings: 10-K · 10-Q